Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (22922)	10/27/2016 2:01:15 PM
From: Goose94	Respond to of 202736

SL-Cse halted

To: Goose94 who wrote (22922)	11/14/2016 6:55:06 PM
From: Goose94	Read Replies (1) \| Respond to of 202736

Supreme Pharmaceuticals (SL-Cse) Nov 14, '15 has entered into an agreement with Canaccord Genuity Corp. on behalf of a syndicate of underwriters pursuant to which the underwriters have agreed to purchase, on a bought deal private placement basis, $40-million aggregate principal amount of convertible debenture units at a price of $1,000 per convertible debenture unit. Each convertible debenture unit will consist of $1,000 principal amount of 10-per-cent senior unsecured convertible debentures and 770 common share purchase warrants of the company. Each warrant will be exercisable to acquire one common share of the company at an exercise price of $1.70 per warrant share for a period of three years following the closing date (as hereinafter defined) of the offering, subject to the company's right to accelerate expiry in certain circumstances."This offering, which is one of the largest financings in the Canadian cannabis sector to date, provides Supreme the capital to complete its 7 Acres hybrid greenhouse and positions Supreme to be one of the world's fastest-growing legal cannabis companies," said John Fowler, chief executive officer of Supreme. The convertible debentures will bear interest from the date of closing at 10.0 per cent per annum, payable semi-annually on June 30 and Dec. 31 of each year and will mature on Dec. 31, 2019. Subject to any required regulatory approval and provided no event of default has occurred and is continuing, the company shall have the option to pay such interest by delivering such number of freely tradable common shares of the company as may be required to a trustee for sale, in which event holders of the convertible debentures will be entitled to receive a cash payment equal to the interest owed from the proceeds of the sale of such requisite number of common shares by the trustee. The convertible debentures will be convertible at the option of the holder into common shares at any time prior to the close of business on the maturity date at a conversion price of $1.30 per common share. Beginning on the date that is four months and one day following the closing date, the company may force the conversion of all of the principal amount of the then-outstanding convertible debentures at the conversion price on 30 days prior written notice should the daily volume-weighted average trading price of the common shares be greater than $1.75 for any 15 consecutive trading days. The convertible debentures will be subject to redemption, in whole or in part, by the company at any time after 24 months upon giving holders not fewer than 30 and not more than 60 days prior written notice, at a price equal to the then-outstanding principal amount of the convertible debentures plus all accrued and unpaid interest up to and including the redemption date. Upon a change of control of the company, holders of the convertible debentures will have the right to require the company to repurchase their convertible debentures, in whole or in part, on the date that is 30 days following the giving of notice of the change of control, at a price equal to 104 per cent of the principal amount of the convertible debentures then outstanding plus accrued and unpaid interest thereon. If 90 per cent or more of the principal amount of the convertible debentures outstanding on the date of the notice of the change of control has been tendered for redemption, the company will have the right to redeem all of the remaining convertible debentures at the offer price. The convertible debentures and the warrants comprising the convertible debenture units and any common shares issuable upon conversion or exercise thereof, as applicable, will be subject to a statutory hold period lasting four months and one day following the closing date. The company intends to use the net proceeds of the offering for expanding the operating footprint of the company's hybrid greenhouse facility in Kincardine, Ont., working capital and general corporate purposes. Closing of the offering is expected to occur on or about Dec. 7, 2016. The offering is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange. About Supreme Supreme is a Canadian publicly traded company committed to becoming a leading supplier of affordable medical cannabis through its wholly owned subsidiary 7 Acres (formerly AMMCan). 7 Acres is a federally licensed producer of medical cannabis pursuant to the ACMPR operating a 342,000-square-foot hybrid greenhouse facility. The hybrid greenhouse combines the best technology of indoor production with the efficiencies and sustainability of a greenhouse, in a single large-format production footprint. Supreme Pharmaceuticals Inc. Investor Relations (416) 630-7272 info@supreme.ca www.supreme.ca